pp-233 Solution for infusion
Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Congenital Myasthenic Syndromes (CMS) / Clinical stage: Phase 3 / Modality: Biologic - first-in-class agonist antibody targeting muscle-specific kinase (MuSK) / Mechanism & Target: MuSK agonist; novel mechanism for CMS / Route & form: IV / Differentiation: First-in-class MuSK agonist; addresses rare neuromuscular disorder
Manufacturer #39439
| International biotechnology company focused on rare and severe autoimmune diseases. Develops FcRn-modulating and complement-targeting biologics for neuromuscular and immune-mediated conditions. Advances multiple Phase 3 programs through global clinical development. |
None